INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
INNOVATE (VATE) GlobeNewswire·2025-03-31 20:04- Life Sciences: MediBeacon Transdermal GFR ("TGFR") system received FDA approval to assess kidney - Infrastructure: DBM Global fourth quarter revenue of $225.7 million - function - - Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE: VATE) announced today its consolidated results for the fourth quarter. Financial Summary | (in millions, except per share amount ...